Sarah K Tasian, MD

faculty photo
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Children's Hospital of Philadelphia
Department of Pediatrics, Division of Oncology and Center for Childhood Cancer Research
University of Pennsylvania School of Medicine and Abramson Cancer Center
3501 Civic Center Boulevard, CTRB 3056
Philadelphia, PA 19104
Education:
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of comprehensive leukemia genetic data with therapy selection for children with high risk newly-diagnosed and relapsed ALL and AML with a focus on precision medicine treatment approaches.

I attend on the Hematologic Malignancies inpatient service and outpatient Oncology clinic at the Children's Hospital of Philadelphia. I have procedural expertise in bone marrow aspiration and biopsy, lumbar punctures (spinal taps), Ommaya reservoir taps, administration of intrathecal chemotherapy, and skin biopsies.

Description of Other Expertise

I am a primary clinical mentor in Hematologic Malignancies for first, second, and third year pediatric hematology-oncology fellows and supervise their patient care in the inpatient and outpatient clinical settings. I also teach and supervise pediatric residents in the inpatient setting.

Description of Research Expertise

My career goal as an academic physician-scientist is to develop molecularly-targeted therapies for children with high-risk leukemias to prevent relapse, improve survival, and minimize toxicities.

My independent translational research program focuses upon novel therapeutics for high-risk pediatric leukemias via:
(1) Characterization of signal transduction networks and preclinical testing of kinase inhibitors for subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
(2) Preclinical testing of leukemia antigen-redirected chimeric antigen receptor (CAR) T cell immunotherapy for childhood AML and ALL
(3) Early phase clinical trial testing of targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia

Successful integration of our bench-based and clinical studies has led to several trials testing new therapies in children with high-risk leukemias. I have leadership roles in the COG ALL, Myeloid Diseases, and AML New Agents steering committees and am the COG Developmental Therapeutics Committee Vice Chair of Biology for Hematologic Malignancies. I also chair the COG phase 2 clinical trial AALL1521 (ruxolitinib/chemotherapy for children with CRLF2/JAK pathway-mutant Ph-like ALL), co-lead development of immunotherapy trials for children with relapsed AML, and am PI of the CHOP Center for Childhood for Cancer Research leukemia biorepository.

Current Tasian laboratory members and collaborators:
Asen Bagashev, PhD (research associate/scientist)
John Chukinas, BS (research technician)
Yang Ding, MD (post-doctoral fellow/instructor)
David Hottman Allen, PhD (post-doctoral fellow)
Christian Hurtz, PhD (research associate/scientist)
JP Loftus, BS (research technician)
Lisa Niswander, MD PhD (post-doctoral fellow)
Sisi Zheng, MD (post-doctoral fellow)

Selected Publications

Tasian SK.: Are we ABL to do better for children with BCR-ABL1-like acute lymphocytic leukaemia? Lancet Haematol 8: e6-e8, Jan 2021.

Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK.: Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer 68: e28718, Jan 2021.

Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K.: Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discov 2021 Notes: online ahead of print.

Si SJ, Tasian SK, Bassiri H, Fisher BT, Atalla J, Patel R, Romberg N, Lambert MP, Paessler M, Behrens EJ, Teachey DT, Sullivan KE.: Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. J Clin Immunol Clin Immunol, 2021.

Tasian SK, Peters C.: Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia? Lancet Haematol 7: e858-e859, Dec 2020.

Hurtz C, Wertheim GB, Bhansali R, Lee SJ, Kumar A, Lehman A, Jeschke GR, Crispino J, Besson T, Shi J, Swaminathan S, Tasian SK, Carroll M: DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia. Blood Page: 699, December 2020 Notes: ASH annual meeting; oral presentation given by collaborator (meeting held virtually due to viral pandemic).

Rabin KR, Devidas M, Chen Z, Dai Y, Tasian SK,Hitlzer JK, Roberts KG, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Mullighan CG, Harvey RC, Chen I-M, Willman CL, Reshmi SC, Gastier-Foster JM, Maloney KW, Larsen EC, Schore RJ, Burke MJ, Salter WL, Winick NJ, Carroll WL, Raetz EA, Angiolillo AL, Loh ML,Hunger SP : Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group (COG). Blood Page: 1094, December 2020 Notes: ASH annual meeting; poster presentation by collaborator (meeting held virtually due to viral pandemic).

Tasian SK, Dai Y, Devidas M, Roberts KG, Harvey RC, Chen I-M, Carroll AJ, Heerema NA, Reshmi SC, Gastier-Foster JM, Borowitz MJ, Wood BL, Mullighan CG, Willman CL, Maloney KW, Larsen EC, Angiolillo AL, Schore RJ, Burke MJ, Salter WL, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Rabin KR, Loh ML: Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: a Report from the Children’s Oncology Group Blood Page: 1095, December 2020 Notes: poster presentation at ASH annual meeting (held virtually due to viral pandemic).

Vadakekolathu J, Yau T-O, Altmann H, Minden MD, Davidson-Moncada JK, Tasian SK, Bornhäuser M, Goto I, Luznik L, Rutella S: An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. Blood Page: 33, December 2020 Notes: ASH annual meeting; oral presentation given by collaborator (meeting held virtually due to viral pandemic).

Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E.: Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica Online ahead of print, Dec 2020.

back to top
Last updated: 04/08/2021
The Trustees of the University of Pennsylvania